Ear injection aims to repair Diabetes-Linked hearing damage

NCT ID NCT07472907

Not yet recruiting Symptom relief Sponsor: Cilcare SAS Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a single injection of CIL001 (Paliroden) into the ear to repair nerve damage that causes hearing problems in people with type 2 diabetes. The trial includes 135 adults aged 45-75 with diabetes for at least 5 years. Researchers will check safety and whether the injection improves the ability to hear speech in noisy settings.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

CIL001 (Paliroden)

What this could lead to

If it works, this could point toward a treatment for hearing loss caused by diabetes, and possibly help delay dementia.

What could go wrong

This is an early-phase trial with only 135 people, so results may not apply widely. The injection is new and safety is still being checked.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus Hearing Loss, Hidden type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COCHLEAR SYNAPTOPATHY